Exploration of 3-Aminoazetidines as Triple Reuptake Inhibitors by Bioisosteric Modification of 3-alpha-Oxyazetidine
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Han, Minsoo | - |
dc.contributor.author | Song, Chiman | - |
dc.contributor.author | Jeong, Nakcheol | - |
dc.contributor.author | Hahn, Hoh-Gyu | - |
dc.date.accessioned | 2021-09-05T05:34:54Z | - |
dc.date.available | 2021-09-05T05:34:54Z | - |
dc.date.created | 2021-06-15 | - |
dc.date.issued | 2014-09 | - |
dc.identifier.issn | 1948-5875 | - |
dc.identifier.uri | https://scholar.korea.ac.kr/handle/2021.sw.korea/97478 | - |
dc.description.abstract | For a development of broad spectrum antidepressant 3-aminoazetidine derivatives, two series of compounds were explored by bioisosteric modification of 3-a-oxyazetidine. We synthesized 166 novel 3-aminoazetidine derivatives in series A and B, starting from Boc-protected 3-azetidinone (3) and Boc-protected 3-azetidinal (9) respectively, through parallel syntheses. The inhibitory reuptake activities against serotonin (5-HT), norepinephrine (NE), and dopamine (DA) neurotransmitters were measured by the Neurotransmitter Transporter Uptake Assay Kit using the human embryonic kidney 293 (HEK293) cells stably transfected with the respective three kinds of human transporters (hSERT, hNET, and hDAT). Our study aimed to identify compounds having relative inhibitory activities against hSERT > hNET > hDAT. Lead optimization including microsomal stability, CYP, hERG assay, Ames test, BBB, and PK study resulted in the identification of compound 10dl as a candidate for further studies. | - |
dc.language | English | - |
dc.language.iso | en | - |
dc.publisher | AMER CHEMICAL SOC | - |
dc.subject | MAJOR DEPRESSIVE DISORDER | - |
dc.subject | DRUG DESIGN | - |
dc.subject | BUPROPION | - |
dc.subject | SEROTONIN | - |
dc.subject | COMBINATION | - |
dc.subject | STRATEGIES | - |
dc.subject | DOPAMINE | - |
dc.title | Exploration of 3-Aminoazetidines as Triple Reuptake Inhibitors by Bioisosteric Modification of 3-alpha-Oxyazetidine | - |
dc.type | Article | - |
dc.contributor.affiliatedAuthor | Jeong, Nakcheol | - |
dc.identifier.doi | 10.1021/ml500187a | - |
dc.identifier.scopusid | 2-s2.0-84907506775 | - |
dc.identifier.wosid | 000341619800009 | - |
dc.identifier.bibliographicCitation | ACS MEDICINAL CHEMISTRY LETTERS, v.5, no.9, pp.999 - 1004 | - |
dc.relation.isPartOf | ACS MEDICINAL CHEMISTRY LETTERS | - |
dc.citation.title | ACS MEDICINAL CHEMISTRY LETTERS | - |
dc.citation.volume | 5 | - |
dc.citation.number | 9 | - |
dc.citation.startPage | 999 | - |
dc.citation.endPage | 1004 | - |
dc.type.rims | ART | - |
dc.type.docType | Article | - |
dc.description.journalClass | 1 | - |
dc.description.journalRegisteredClass | scie | - |
dc.description.journalRegisteredClass | scopus | - |
dc.relation.journalResearchArea | Pharmacology & Pharmacy | - |
dc.relation.journalWebOfScienceCategory | Chemistry, Medicinal | - |
dc.subject.keywordPlus | MAJOR DEPRESSIVE DISORDER | - |
dc.subject.keywordPlus | DRUG DESIGN | - |
dc.subject.keywordPlus | BUPROPION | - |
dc.subject.keywordPlus | SEROTONIN | - |
dc.subject.keywordPlus | COMBINATION | - |
dc.subject.keywordPlus | STRATEGIES | - |
dc.subject.keywordPlus | DOPAMINE | - |
dc.subject.keywordAuthor | Depression | - |
dc.subject.keywordAuthor | triple reuptake inhibitor | - |
dc.subject.keywordAuthor | 3-aminoazetidines | - |
dc.subject.keywordAuthor | biososterism | - |
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.
(02841) 서울특별시 성북구 안암로 14502-3290-1114
COPYRIGHT © 2021 Korea University. All Rights Reserved.
Certain data included herein are derived from the © Web of Science of Clarivate Analytics. All rights reserved.
You may not copy or re-distribute this material in whole or in part without the prior written consent of Clarivate Analytics.